FDA Panel Examines Zogenix’s Zohydro ER

The new drug application (NDA) for Zogenix/Alkermes/Paladin Labs’ Zohydro ER (hydrocodone bitartrate extended-release capsules) will be reviewed by a panel advising the FDA this week.

To continue reading click here:

To subscribe to the full newsletter please contact us at:

Annie Gustavson
Bloomberg Briefs
agustavson@bloomberg.net
212-617-0544

Bloomberg BRIEF Newsletters

Insight.
Delivered.

Newsletters For Professionals,
From Professionals.



Select Brief to Subscribe
or for a free trial.





Back_issues